Industry Post-Stenting Antiplatelet Trial Gains $1.5 Million Boost From FDA
This article was originally published in The Pink Sheet Daily
Study aims to identify optimum duration of anti-clotting drugs for stent patients; enrollment targeted at 20,000 patients.
You may also be interested in...
Antiplatelets In The Wilderness After Mixed Results From DAPT Study
FDA seems more concerned about mortality than most academics following trial of dual antiplatelet therapy after stenting; AstraZeneca sees potential opening for Brilinta.
Effient Labeling Could Give Edge Against Plavix Through Pharmacogenetics
Lilly/Daiichi Sankyo's prasugrel has carefully constructed label to control risk of bleeding - but it also includes a pharmacogenetic argument that Effient works in clopidogrel non-responders.
High Hopes For Stent Antiplatelet Therapy Trial
FDA, along with the four major drug-eluting stent manufacturers and four antiplatelet drug firms, are months away from launching an unprecedented $100 million, 20,000-patient trial to determine the optimum duration of dual antiplatelet therapy with drug-eluting stents